177 related articles for article (PubMed ID: 37457135)
21. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
22. Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC.
Olaoba OT; Ligali FC; Alabi ZO; Akinyemi AO; Ayinde KS
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188483. PubMed ID: 33232723
[TBL] [Abstract][Full Text] [Related]
23. Orchestration of mesenchymal plasticity and immune evasiveness
Hashimoto A; Handa H; Hata S; Hashimoto S
Front Oncol; 2022; 12():1005566. PubMed ID: 36408139
[TBL] [Abstract][Full Text] [Related]
24. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.
Yang J; Zhang Q; Wang J; Lou Y; Hong Z; Wei S; Sun K; Wang J; Chen Y; Sheng J; Su W; Bai X; Liang T
EBioMedicine; 2022 Apr; 78():103958. PubMed ID: 35316682
[TBL] [Abstract][Full Text] [Related]
25. Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8.
Chen SJ; Lian GD; Li JJ; Zhang QB; Zeng LJ; Yang KG; Huang CM; Li YQ; Chen YT; Huang KH
Cancer Med; 2018 Nov; 7(11):5679-5690. PubMed ID: 30311406
[TBL] [Abstract][Full Text] [Related]
26. An increased expression of long non-coding RNA PANDAR promotes cell proliferation and inhibits cell apoptosis in pancreatic ductal adenocarcinoma.
Jiang Y; Feng E; Sun L; Jin W; You Y; Yao Y; Xu Y
Biomed Pharmacother; 2017 Nov; 95():685-691. PubMed ID: 28886528
[TBL] [Abstract][Full Text] [Related]
27. Microbiome and pancreatic ductal adenocarcinoma.
Tijeras-Raballand A; Hilmi M; Astorgues-Xerri L; Nicolle R; Bièche I; Neuzillet C
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101589. PubMed ID: 33607375
[TBL] [Abstract][Full Text] [Related]
28. Multiphasic Heterogeneity of Fibroblasts in the Microenvironment of Pancreatic Ductal Adenocarcinoma: Dissection and the Sum of the Dynamics.
Ijichi H
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230803
[TBL] [Abstract][Full Text] [Related]
29. The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.
Stouten I; van Montfoort N; Hawinkels LJAC
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240052
[TBL] [Abstract][Full Text] [Related]
30. The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma.
Zhang J; Li R; Huang S
Front Oncol; 2022; 12():951019. PubMed ID: 35965504
[TBL] [Abstract][Full Text] [Related]
31. The tumor stroma influences immune cell distribution and recruitment in a PDAC-on-a-chip model.
Geyer M; Gaul LM; D Agosto SL; Corbo V; Queiroz K
Front Immunol; 2023; 14():1155085. PubMed ID: 37205118
[TBL] [Abstract][Full Text] [Related]
32. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.
Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L
Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754
[TBL] [Abstract][Full Text] [Related]
33. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S
J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515
[TBL] [Abstract][Full Text] [Related]
34. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
[TBL] [Abstract][Full Text] [Related]
35. The Role of Exosomes in Pancreatic Ductal Adenocarcinoma Progression and Their Potential as Biomarkers.
Hsu SK; Jadhao M; Liao WT; Chang WT; Lin IL; Chiu CC
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980662
[TBL] [Abstract][Full Text] [Related]
36. Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance.
Palamaris K; Felekouras E; Sakellariou S
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771695
[TBL] [Abstract][Full Text] [Related]
37. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
38. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells.
Sebens Müerköster S; Werbing V; Sipos B; Debus MA; Witt M; Grossmann M; Leisner D; Kötteritzsch J; Kappes H; Klöppel G; Altevogt P; Fölsch UR; Schäfer H
Oncogene; 2007 Apr; 26(19):2759-68. PubMed ID: 17086212
[TBL] [Abstract][Full Text] [Related]
39. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
40. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway.
Zheng S; Hu C; Lin H; Li G; Xia R; Zhang X; Su D; Li Z; Zhou Q; Chen R
J Exp Clin Cancer Res; 2022 Feb; 41(1):71. PubMed ID: 35189958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]